In vitro activities of new macrolides and rifapentine against Brucella spp | Zendy

J.Á. García-Rodríguez | Zendy; Juan Luis Muñoz Bellido | Zendy; Marı́a José Fresnadillo | Zendy; I Trujillano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activities of new macrolides and rifapentine against Brucella spp

Author(s) -

J.Á. García-Rodríguez,

Juan Luis Muñoz Bellido,

Marı́a José Fresnadillo,

I Trujillano

Publication year - 1993

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.37.4.911

Subject(s) - rifapentine , roxithromycin , clarithromycin , microbiology and biotechnology , azithromycin , moxifloxacin , streptomycin , antibacterial agent , aminoglycoside , erythromycin , in vitro , trimethoprim , antibiotics , biology , medicine , mycobacterium tuberculosis , tuberculosis , biochemistry , pathology , latent tuberculosis

We have tested the in vitro activities of streptomycin, rifampin, tetracyclines, trimethoprim-sulfamethoxazole, erythromycin, four new macrolides (roxithromycin, azithromycin, clarithromycin, and dirithromycin), and rifapentine against 62 strains of Brucella spp. Azithromycin and clarithromycin were, respectively, eight- and twofold more active than erythromycins (MIC for 90% of strains = 2, 8, and 16 micrograms/ml, respectively). The activity of rifapentine was similar to that of rifampin (MIC for 90% of strains = 1 microgram/ml).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research